MCAD Antibody (A-5): sc-365142

MCAD Antibody (A-5) is a mouse monoclonal IgG2a antibody that detects medium-chain acyl-CoA dehydrogenase (MCAD) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). MCAD plays a crucial role in the mitochondrial fatty acid β-oxidation pathway, specifically catalyzing the initial reaction in the breakdown of medium-chain acyl-CoAs ranging from C4 to C12. This enzymatic activity is vital for energy production, particularly during periods of fasting when the body relies on fat stores for fuel. Deficiencies in MCAD can lead to severe metabolic disorders, including fasting hypoglycemia and hepatic dysfunction, which can be life-threatening, especially in infants. MCAD (A-5) antibody recognizes a homotetramer composed of 421 amino acids featuring mitochondrial protein transit peptides, ensuring proper localization within the mitochondria. Notably, MCAD exhibits 88% sequence identity with its porcine counterpart, highlighting evolutionary conservation and importance across species. Anti-MCAD antibody (A-5) serves as an essential tool for researchers studying metabolic pathways and disorders related to fatty acid metabolism.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MCAD Antibody (A-5) References:

1. Mutations in the medium chain acyl-CoA dehydrogenase (MCAD) gene.  |  Tanaka, K., et al. 1992. Hum Mutat. 1: 271-9. PMID: 1363805
2. Expression of wild-type and mutant medium-chain acyl-CoA dehydrogenase (MCAD) cDNA in eucaryotic cells.  |  Jensen, TG., et al. 1992. Biochim Biophys Acta. 1180: 65-72. PMID: 1382617
3. Screening for MCAD deficiency in newborns.  |  Loughrey, C. and Bennett, MJ. 2009. BMJ. 338: b971. PMID: 19282441
4. Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review.  |  Pugliese, M., et al. 2020. Orphanet J Rare Dis. 15: 12. PMID: 31937333
5. MCAD activation by empagliflozin promotes fatty acid oxidation and reduces lipid deposition in NASH.  |  Wang, Y., et al. 2022. J Mol Endocrinol. 69: 415-430. PMID: 35900373
6. Host-microbe co-metabolism via MCAD generates circulating metabolites including hippuric acid.  |  Pruss, KM., et al. 2023. Nat Commun. 14: 512. PMID: 36720857
7. Fenofibrate Attenuates Renal Tubular Cell Apoptosis by Up-Regulating MCAD in Diabetic Kidney Disease.  |  Tang, C., et al. 2023. Drug Des Devel Ther. 17: 1503-1514. PMID: 37223723
8. A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology.  |  Weeks, KL., et al. 2024. J Mol Med (Berl). 102: 95-111. PMID: 37987775
9. Assessing the quality and value of metabolic chart data for capturing core outcomes for pediatric medium-chain acyl-CoA dehydrogenase (MCAD) deficiency.  |  Iverson, R., et al. 2024. BMC Pediatr. 24: 37. PMID: 38216926
10. CACS, CCTA and mCAD-LT score in the pre-transplant assessment of coronary artery disease and the prediction of post-transplant cardiovascular events.  |  Pagano, G., et al. 2024. Liver Int. 44: 1912-1923. PMID: 38591767

The preferred MCAD antibody is MCAD Antibody (E-8): sc-271931.